Gene · 8000
Papers1,687
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,687
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma. | J Transl Med | 2023 | 37817249 | PubTator, text mining | PubMed |
| Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. | Biomark Res | 2023 | 37798621 | PubTator, text mining | PubMed |
| Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy. | Front Immunol | 2023 | 37795091 | PubTator, text mining | PubMed |
| Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. | Transl Oncol | 2023 | 37776617 | PubTator, text mining | PubMed |
| Molecular Profile of Variants in CDH1, TP53, PSCA, PRKAA1, and TTN Genes Related to Gastric Cancer Susceptibility in Amazonian Indigenous Populations. | J Pers Med | 2023 | 37763132 | PubTator, text mining | PubMed |
| Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers. | Int J Mol Sci | 2023 | 37762677 | PubTator, text mining | PubMed |
| Emerging Immunotherapy Approaches for Treating Prostate Cancer. | Int J Mol Sci | 2023 | 37762648 | PubTator, text mining | PubMed |
| TDP-43 Epigenetic Facets and Their Neurodegenerative Implications. | Int J Mol Sci | 2023 | 37762112 | PubTator, text mining | PubMed |
| Recent advances and future perspectives in the therapeutics of prostate cancer. | Exp Hematol Oncol | 2023 | 37740236 | PubTator, text mining | PubMed |
| Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach. | Cell Rep Med | 2023 | 37738978 | PubTator, text mining | PubMed |
| Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. | J Clin Invest | 2023 | 37725435 | PubTator, text mining | PubMed |
| Bladder cancer course, four genetic high-risk variants, and histopathological findings. | EXCLI J | 2023 | 37720238 | PubTator, text mining | PubMed |
| Differentially Expressed Genes, miRNAs and Network Models: A Strategy to Shed Light on Molecular Interactions Driving HNSCC Tumorigenesis. | Cancers (Basel) | 2023 | 37686696 | PubTator, text mining | PubMed |
| Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. | Cancers (Basel) | 2023 | 37686543 | PubTator, text mining | PubMed |
| Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers. | Cancer Med | 2023 | 37668041 | PubTator, text mining | PubMed |
| Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer. | BMC Med | 2023 | 37667257 | PubTator, text mining | PubMed |
| Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. | Heliyon | 2023 | 37664750 | PubTator, text mining | PubMed |
| Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. | Cell Immunol | 2023 | 37660477 | PubTator, text mining | PubMed |
| The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology. | Sci Rep | 2023 | 37660159 | PubTator, text mining | PubMed |
| Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. | Nat Commun | 2023 | 37660083 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8000/papers?page=7